Marcel Nijland
dr.
I work as a hematologist and my main focus is on patients with aggressive B-cell lymphomas and CNS lymphomas. My research is centered on the application of novel diagnostic and therapeutic strategies into clinical trials. These include imaging-studies like 18F-FDG-PET, Zr-Brentuximab-PET and Zr-atezolizumab-PET. In addition, I aim to implement novel strategies to measure minimal residual disease, and prognostic gene expression profiles in DLBCL. Linked to this I also focus on mutational analysis to study clonal evolution and prognostic / predictive values of mutations. These studies are carried out in a close collaboration with HOVON and other departments in the UMCG.
Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study
Published in: Blood
Access to document
10.1182/bloodadvances.2021004295
document
In 2017, the European Medicines Agency approved rituximab biosimilars (R-biosimilars) for treatment of diffuse large B-cell lymphoma (DLBCL). Thereafter, the Netherlands was one of the first countries to implement R-biosimilars, given lower costs compared with rituximab originator (R-originator). This study’s objective was to investigate whether overall survival (OS) of patients with DLBCL receiving R-biosimilars is similar to patients treated with R-originator. DLBCL patients >18 years, diagnosed between 2014 and 2018, who received at least 1 cycle of rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) were identified...
Mirian Brink, Xaver U. Kahle, Joost S. P. Vermaat, Josee M. Zijlstra, Martine Chamuleau, Marie Jose Kersten, Mujde Durmaz, Wouter J. Plattel, Pieternella J. Lugtenburg, Wendy Stevens, Rogier Mous, Elisabeth G. E. de Vries, Marjolein W. M. van der Poel, Prashant V. Nannan Panday, Gerwin Huls, Tom van Meerten, Marcel Nijland
Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study
Published in: Haematologica
Access to document
10.3324/haematol.2019.243238
document
Achieving a metabolic complete response (mCR) before high-dose chemotherapy (HDC) and autologous peripheral blood stem-cell transplant (auto-PBSCT) predicts progression free survival (PFS) in relapsed/refractory classical Hodgkin lymphoma (R/R cHL). We added brentuximab vedotin (BV) to DHAP to improve the mCR rate. In a Phase I dose-escalation part in 12 patients, we showed that BV-DHAP is feasible. This Phase II study included 55 R/R cHL patients (23 primary refractory). Treatment consisted of three 21-day cycles of BV 1.8 mg/kg on day 1, and DHAP (dexamethasone 40mg days 1-4, cisplatin...
Marie José Kersten, Julia Driessen, Josée M Zijlstra, Wouter J Plattel, Franck Morschhauser, Pieternella J Lugtenburg, Pauline Brice, Martin Hutchings, Thomas Gastinne, Roberto Liu, Coreline N Burggraaff, Marcel Nijland, Sanne H Tonino, Anne I J Arens, Roelf Valkema, Harm van Tinteren, Marta Lopez-Yurda, Arjan Diepstra, Daphne De Jong, Anton Hagenbeek
Primary therapy and survival in patients over 70 years old with primary central nervous system lymphoma: a contemporary, nationwide, population-based study in the Netherlands
Published in: Haematologica
Access to document
10.3324/haematol.2020.247536
document
Matthijs van der Meulen, Jacoline E C Bromberg, Marcel Nijland, Otto Visser, Jeanette K Doorduijn, Avinash G Dinmohamed
Machine Learning in the Differentiation of Follicular Lymphoma from Diffuse Large B-cell Lymphoma with Radiomic [18F]FDG PET/CT Features
Filipe Montes de Jesus, Yunchao Yin, Elissavet Mantzorou-Kyriaki, Xaver Kahle, Robbert de Haas, Derya Yakar, Andor W.J.M. Glaudemans, Walter Noordzij, Thomas Kwee, Marcel Nijland
Borrelia burgdorferi mimicking central nervous system relapse in diffuse large B cell lymphoma
Published in: Annals of Hematology
Access to document
10.1007/s00277-020-04022-5
document